Tempus AI vs Veritone Inc — how do they compare? Tempus AI trades at $61.16 (market cap $11.67B), while Veritone Inc trades at $0.87 (market cap $91.43M). The key difference: Tempus AI is far larger — about 127.6× Veritone Inc's market cap, and Tempus AI is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals.
| TEM | VERI | |
|---|---|---|
Market Cap | $11.67B | $91.43M |
Sector | Broad Market / Factor | Technology |
52-Week High | $103.25 | $8.39 |
52-Week Low | $41.55 | $0.79 |
Enterprise Value | $12.30B | $126.82M |
Signals from Pluang's Aura AI — not financial advice
Tempus AI (TEM) trades at $64.29, down 0.51% on the day, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats despite negative profitability, with a P/S of 7.99 and P/B of 26.23. Recent catalysts include FDA clearance for an AI ECG product and a $9.5 million ARPA-H award for autonomous AI in cardiology (Business Wire, September 9, 2026).
Outlook remains positive given analyst consensus and growth in precision medicine, but risks include sustained losses, high valuation multiples, and cash burn. The consensus price target is $69.11, implying potential upside, though investors must weigh the company's unprofitability against its innovation pipeline and market position.
Veritone (VERI) trades at $0.9155, up 0.99% on the day, amid a bearish technical signal with mixed oscillators. The company reported Q2 2026 revenue of $24.3 million, up 20% sequentially, but continues to post significant losses, with a net income margin of -117.54% in 2025. Recent news highlights a securities class action investigation announced by Kaskela Law on August 20, 2026, adding legal overhangs to operational challenges.
The outlook remains challenged by persistent unprofitability and negative cash flow from operations, offset by a balanced analyst consensus of 46% buy and 46% hold ratings. Key risks include ongoing legal scrutiny, high operating costs, and the need to achieve sustainable profitability to support the stock's valuation.
Trailing returns across standard periods
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →